Prestige Consumer Healthcare Inc.
Acquisitions
7
Major Deals Covered
$2.9B
Disclosed Deal Value
Prestige Consumer Healthcare's largest disclosed acquisition here is Breathe Right and other brands (Foundation Consumer Healthcare) for $1B in 2026. This page covers 7 major deals from 2012 to 2026, each with its price where disclosed and the reason behind it.
| Company | Year | Price | Purpose |
|---|---|---|---|
| 17 OTC brands from GlaxoSmithKline | 2012 | $660.0M | Added BC, Goody's, Ecotrin, Beano and other OTC brands, making healthcare the core of Prestige. |
| Hydralyte | 2014 | Undisclosed | Added an oral rehydration brand that anchors the Australian business. |
| C.B. Fleet Company | 2017 | $825.0M | Added Fleet and Summer's Eve, expanding women's health and gastrointestinal categories. |
| Akorn consumer health business (TheraTears) | 2021 | $230.0M | Expanded eye care alongside Clear Eyes. |
| Pillar5 Pharma | 2025 | Undisclosed | Bought a Clear Eyes manufacturer to secure eye care production capacity. |
| Breathe Right and other brands (Foundation Consumer Healthcare) | 2026 | $1.0B | Added Breathe Right nasal strips plus Anbesol, Dimetapp and other brands with about $200 million of revenue; about $900 million net of expected tax benefits. Closed June 15, 2026. |
| LaCorium Health | 2026 | $150.0M | Added an Australian therapeutic skin care business for about $150 million in cash. Closed July 1, 2026. |
2026
$1.0B
Added Breathe Right nasal strips plus Anbesol, Dimetapp and other brands with about $200 million of revenue; about $900 million net of expected tax benefits. Closed June 15, 2026.
2026
$150M
Added an Australian therapeutic skin care business for about $150 million in cash. Closed July 1, 2026.
2025
Bought a Clear Eyes manufacturer to secure eye care production capacity.
2021
$230M
Expanded eye care alongside Clear Eyes.
2017
$825M
Added Fleet and Summer's Eve, expanding women's health and gastrointestinal categories.
2014
Added an oral rehydration brand that anchors the Australian business.
2012
$660M
Added BC, Goody's, Ecotrin, Beano and other OTC brands, making healthcare the core of Prestige.
Growth comes from two sources. Organically, Prestige targets low single-digit growth through brand marketing, e-commerce and line extensions, plus restoring Clear Eyes supply via the Pillar5 Pharma facility and a new high-speed line. Inorganically, it buys established OTC brands that larger companies no longer prioritize: in 2026 it acquired Breathe Right and other brands from Foundation Consumer Healthcare for $1.045 billion (about $900 million net of expected tax benefits) and LaCorium Health in Australia for about $150 million.
Prestige makes money by selling branded OTC healthcare products to retailers (mass merchants, drug stores, grocery, club, dollar and e-commerce) in North America and to pharmacy and retail channels internationally, led by Australia. It reports two segments: North American OTC Healthcare and International OTC Healthcare. Most products are made by third-party contract manufacturers, so the company concentrates on brand marketing, retail execution, regulatory compliance and supply management. Capital spending is low, which turns much of operating profit into free cash flow ($246.4 million in FY2026). That cash funds debt paydown, share repurchases and acquisitions of established OTC brands, the main source of portfolio growth. The 2025 purchase of Pillar5 Pharma, a Clear Eyes supplier, was a partial step away from pure outsourcing to secure eye care capacity.
Breathe Right and other brands for $1.045 billion (2026), C.B. Fleet for $825 million (2017), 17 GSK OTC brands for $660 million (2012), Akorn's consumer health business for $230 million (2021) and LaCorium for about $150 million (2026).
Breathe Right nasal strips plus Anbesol, Dimetapp and other brands from Foundation Consumer Healthcare, a portfolio with about $200 million of revenue.
The Fleet acquisition added iconic digestive care and feminine hygiene brands (Fleet, Summer's Eve), instantly increasing annual revenues by over $200 million, diversifying the portfolio into high-volume recurring personal care, and expanding manufacturing presence in Lynchburg, Virginia.
Breathe Right was a classic neglected corporate orphan inside pharmaceutical giant GlaxoSmithKline. Prestige acquired the brand to expand into non-medicated sleep and nasal congestion, immediately enhancing gross margins and giving Prestige a global distribution platform across Europe and Asia.
Prestige evaluates OTC brand targets that hold #1 or #2 market share in non-prescription categories, generate 50%+ gross margins, possess multi-generational consumer brand equity, and can be integrated into Prestige's outsourced distribution architecture without adding corporate overhead.
Prestige finances acquisitions through a balanced mix of senior secured credit facilities, low-cost institutional term loans, and balance sheet cash flow, prioritizing aggressive debt paydown over the subsequent 24 to 36 months to return leverage to target levels.
Yes. In addition to divesting its entire household cleaning division for $397 million in 2018, Prestige periodically prunes sub-scale, low-margin regional brands to keep corporate focus tightly centered on core high-return OTC platforms.
During periods of elevated borrowing costs, Prestige pauses large debt-funded mega-acquisitions, focusing capital on paying down floating-rate debt, repurchasing its own undervalued stock, and evaluating smaller tuck-in brand additions.
Compare corporate acquisition records, deal values, and strategic targets
Explore Prestige Consumer Healthcare
Core profile pages, founders and related research hubs for this company.